Abstract
Since the first reported work on insect cells by Goldschmidt in 1915, more than 600 insect cell lines have been established. With the generation of the first recombinant baculovirus in the late 1980s, the application of insect cell lines for expression of heterologous gene products grew exponentially. Today, the insect cell-baculovirus system is well accepted as a universal manufacturing platform, as demonstrated by the number of approved veterinary and human vaccines. In addition, insect cells are an inexpensive, safe and efficient alternative to human and animal-derived cell lines for studying host-pathogen interactions, cell metabolism, or cellular and humoral immunity, as well as for the production of gene delivery vectors for human gene therapy, for example, modified baculoviruses and mammalian vectors generated via adeno-associated virus. In the longer term, the comprehensive understanding of the regulation and fate of insect stem cells may enable the use of insect cells as a model organism for the development of novel therapies for human diseases. In this chapter, the potential of insect cells is thoroughly discussed, from the basic concepts in cell culture to their requirements in terms of up- and down-stream processing as well as the regulatory hurdles.
| Original language | English |
|---|---|
| Title of host publication | Industrial Scale Suspension Culture of Living Cells |
| Publisher | Wiley/Blackwell |
| Pages | 348-389 |
| Number of pages | 42 |
| ISBN (Electronic) | 978-352768332-1 |
| ISBN (Print) | 978-352733547-3 |
| DOIs | |
| Publication status | Published - 4 Aug 2014 |
Keywords
- Biomedicine and biopharmaceuticals
- Bioreactor design
- Expression system
- Insect cells
- Metabolism
- Up- and down-stream processing